Retatrutide Hilma Biocare

Retatrutide by Hilma Biocare (LY-3437943) is a next-generation weight-loss peptide and one of the most powerful metabolic agents in the category. It is a triple receptor agonist, acting on GLP-1, GIP and the glucagon receptor (GCGR) at once — a step beyond single- and dual-agonist drugs. This 39-amino-acid peptide is resistant to DPP-4 cleavage, giving it a long, stable action. It is studied for the treatment of obesity and type 2 diabetes, improving glycemic control alongside diet and exercise.

Effects and benefits

By hitting three metabolic receptors, Retatrutide combines strong appetite suppression with improved insulin response and increased energy expenditure through the glucagon pathway. That triple action is why it is associated with some of the largest weight-loss results seen in the GLP-1 category.

• Very strong appetite control
• Improved glycemic control
• Added energy-expenditure effect via GCGR
• Long, stable action (DPP-4 resistant)

Usage and administration

Retatrutide is injected subcutaneously once weekly, always starting low and titrating up slowly to manage nausea and GI effects. As a metabolic agonist it belongs alongside the rest of the peptides range rather than in a performance cycle.

Related products

Those comparing GLP-1 options often look at the single-agonist Semaglutide or the dual-agonist Tirzepatide as gentler starting points.

Why choose Hilma Biocare

Every vial is produced to consistent pharmaceutical standards with dependable dosing you can trust. Explore the full Hilma Biocare catalogue for matching metabolic products.